What due diligence should an investor run before backing a brand in the Cannabidiol (CBD) Market?

Verify GMP certification, third-party potency and pesticide testing records, and payment processor stability. Ask specifically about rolling reserve balances, which reveal working capital fragility that revenue figures hide [15]. Read More

How should a retailer evaluate supplier quality claims?

Demand batch-level certificates of analysis from ISO 17025-accredited laboratories, not in-house results. Cross-check that cannabinoid content matches label claim within 10%, the tolerance most state enforcement actions apply [13]. Read More

Does isolate or full-spectrum offer better commercial positioning in the Cannabidiol (CBD) Market?

Isolate travels across borders more easily and passes THC-limit screening. Full-spectrum commands higher prices where legal but restricts export eligibility, so most scaled brands maintain both platforms [16]. Read More

What integration challenges arise when adding cannabinoids to existing consumer product lines?

Shared manufacturing lines require dedicated equipment or validated cleaning protocols to prevent cross-contamination. Insurance carriers also frequently exclude cannabinoid liability, forcing separate policies before production begins [15]. Read More

Which emerging use cases deserve attention beyond wellness and pharmaceuticals?

Sports recovery and perimenopausal symptom management are drawing clinical interest with defined outcome measures. Both target audiences with high willingness to pay and existing practitioner touchpoints [6]. Read More

How does the Cannabidiol (CBD) Market handle cross-border product registration?

Each jurisdiction requires separate dossiers with distinct toxicology and stability data. Firms typically budget 9–18 months and USD 250,000–600,000 per major market entry [4][11]. Read More

What contractual protections matter most in supply agreements?

Insist on potency guarantees with price adjustment clauses tied to assay results, plus regulatory change termination rights. Input prices have fallen sharply, making fixed long-term pricing a liability [9]. Read More

Cannabidiol (CBD) Market (2026 - 2035)

ID: MRFR/HC/6618-CR 200 Pages Vikita Thakur Last Updated: September 15, 2026

Cannabidiol (CBD) Market Research Report: Size, Share, Trend Analysis By Applications (Food Beverages, Health Products, Cosmetics, Pharmaceuticals, Pet Care), By Extract Type (Full Spectrum, Broad Spectrum, Isolate), By Distribution Channel (Online, Retail Stores, Pharmacies), By Form (Oils, gels, Capsules, Edibles, Topicals) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Cannabidiol (CBD) Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)14.85%

2025 Market SizeUSD 10.72 Billion

2035 Market SizeUSD 43.15 Billion

Key Players

Jazz Pharmaceuticals

Canopy Growth Corporation

Charlotte's Web Holdings

Tilray Brands

Curaleaf Holdings

cbdMD Inc.

Trends

Rescheduling Rewrites the Distribution Map
A Pharmaceutical Pipeline That Finally Has Depth
Delivery Technology as the Real Differentiator

Opportunities

Prescription-Adjacent Formulations
Veterinary and Companion Animal Channels
Asia-Pacific Regulatory Openings

Summary Table of Contents Segmentation Download PDF

1 Market Summary |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Key Report Takeaways |
1. 2.1 By Source |
2. 2.2 By End Use |
3. 2.3 By Geography
3 Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2024) |
2. 3.2 Base Year Estimate (2025) |
3. 3.3 Forecast Market Size (2026–2035) |
4. 3.4 Year-over-Year Growth Analysis
4 Driver Impact Analysis |
1. 4.1 Rescheduling and Distribution Access |
2. 4.2 Pharmaceutical Cannabinoid Pipeline Depth |
3. 4.3 Delivery Technology Differentiation |
4. 4.4 Channel Economics and Digital Commerce
5 Restraints Impact Analysis |
1. 5.1 Fragmented Regulatory Frameworks |
2. 5.2 Absent Dietary Supplement Pathway |
3. 5.3 Banking, Payments and Advertising Constraints
6 Opportunities |
1. 6.1 Prescription-Adjacent Formulations |
2. 6.2 Veterinary and Companion Animal Channels |
3. 6.3 Asia-Pacific Regulatory Openings |
4. 6.4 Traceability Data Monetisation |
5. 6.5 Beverage Formats at Scale
7 Regional Market Share & Country-Level Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Precision Dosing and Pharmacogenomics |
2. 8.2 Platform Economics in Contract Manufacturing |
3. 8.3 Interoperable Compliance Infrastructure |
4. 8.4 Evidence-Led Reimbursement
9 Market Segmentation Analysis |
1. 9.1 By Source | |
  1. 9.1.1 Hemp | |
  2. 9.1.2 Marijuana |
2. 9.2 By End Use | |
  1. 9.2.1 Pharmaceuticals | |
  2. 9.2.2 Wellness & Personal Use | |
  3. 9.2.3 Food & Beverages | |
  4. 9.2.4 Pet Care | |
  5. 9.2.5 Others |
3. 9.3 By Product Form | |
  1. 9.3.1 Oils & Tinctures | |
  2. 9.3.2 Capsules & Softgels | |
  3. 9.3.3 Gummies & Confectionery | |
  4. 9.3.4 Topicals & Cosmetics | |
  5. 9.3.5 Beverages | |
  6. 9.3.6 Others |
4. 9.4 By Distribution Channel | |
  1. 9.4.1 Hospital & Specialty Pharmacies | |
  2. 9.4.2 Retail Stores | |
  3. 9.4.3 E-commerce | |
  4. 9.4.4 Others
10 Competitive Landscape |
1. 10.1 Market Concentration Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 Jazz Pharmaceuticals | |
  2. 10.3.2 Canopy Growth Corporation | |
  3. 10.3.3 Charlotte's Web Holdings | |
  4. 10.3.4 Tilray Brands | |
  5. 10.3.5 Curaleaf Holdings | |
  6. 10.3.6 cbdMD Inc. | |
  7. 10.3.7 CV Sciences Inc. | |
  8. 10.3.8 Aurora Cannabis | |
  9. 10.3.9 Medical Marijuana Inc. | |
  10. 10.3.10 Endoca BV | |
  11. 10.3.11 Elixinol Wellness
11 Recent News & Developments
12 Report Scope & Methodology |
1. 12.1 Study Period & Base Year |
2. 12.2 Data Sources & Triangulation |
3. 12.3 Abbreviations
13 Detailed Sources & Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Global CBD Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global CBD Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Global CBD Market – Driver Impact Analysis Matrix, 2026–2035 |
TABLE 4 Global CBD Market – Restraint Impact Analysis Matrix, 2026–2035 |
TABLE 5 Global CBD Market Size, by Source, 2021–2035 (USD Billion) |
TABLE 6 Global CBD Market Size, by End Use, 2021–2035 (USD Billion) |
TABLE 7 Global CBD Market Size, by Product Form, 2021–2035 (USD Billion) |
TABLE 8 Global CBD Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 9 Global CBD Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 10 North America CBD Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Europe CBD Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 12 Asia-Pacific CBD Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 13 South America CBD Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 14 Middle East & Africa CBD Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 15 North America CBD Market Size, by Source, 2021–2035 (USD Billion) |
TABLE 16 North America CBD Market Size, by End Use, 2021–2035 (USD Billion) |
TABLE 17 North America CBD Market Size, by Product Form, 2021–2035 (USD Billion) |
TABLE 18 North America CBD Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 19 Europe CBD Market Size, by Source, 2021–2035 (USD Billion) |
TABLE 20 Europe CBD Market Size, by End Use, 2021–2035 (USD Billion) |
TABLE 21 Europe CBD Market Size, by Product Form, 2021–2035 (USD Billion) |
TABLE 22 Europe CBD Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 23 Asia-Pacific CBD Market Size, by Source, 2021–2035 (USD Billion) |
TABLE 24 Asia-Pacific CBD Market Size, by End Use, 2021–2035 (USD Billion) |
TABLE 25 Asia-Pacific CBD Market Size, by Product Form, 2021–2035 (USD Billion) |
TABLE 26 Asia-Pacific CBD Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 27 South America CBD Market Size, by End Use, 2021–2035 (USD Billion) |
TABLE 28 South America CBD Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 29 Middle East & Africa CBD Market Size, by End Use, 2021–2035 (USD Billion) |
TABLE 30 Middle East & Africa CBD Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 31 US CBD Market Size, by Product Form, 2021–2035 (USD Billion) |
TABLE 32 Germany CBD Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 33 Japan CBD Market Size, by End Use, 2021–2035 (USD Billion) |
TABLE 34 Brazil CBD Market Size, by Source, 2021–2035 (USD Billion) |
TABLE 35 Competitive Benchmarking Matrix – Global CBD Market, 2026 |
TABLE 36 Company Profiles – Key Players, Global CBD Market |
TABLE 37 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 38 Report Scope & Methodology Summary |
TABLE 39 Detailed Sources & Citations Index
16 LIST OF FIGURES |
FIGURE 1 Global CBD Market – Market Dynamics Overview (Drivers, Restraints, Opportunities) |
FIGURE 2 Global CBD Market – Industry Value Chain Analysis |
FIGURE 3 Global CBD Market – Porter's Five Forces Analysis |
FIGURE 4 Global CBD Market – Market Size Trend Line, 2021–2035 (USD Billion) |
FIGURE 5 Global CBD Market – Year-over-Year Growth Curve, 2022–2035 |
FIGURE 6 Global CBD Market Share, by Source, 2025 vs 2035 (%) |
FIGURE 7 Global CBD Market Share, by End Use, 2025 vs 2035 (%) |
FIGURE 8 Global CBD Market Share, by Product Form, 2025 (%) |
FIGURE 9 Global CBD Market Share, by Distribution Channel, 2025 (%) |
FIGURE 10 Global CBD Market Share, by Region, 2025 (%) |
FIGURE 11 North America CBD Market Share, by Country, 2025 (%) |
FIGURE 12 Europe CBD Market Share, by Country, 2025 (%) |
FIGURE 13 Asia-Pacific CBD Market Growth Rate, by Country, 2026–2035 (%) |
FIGURE 14 South America and Middle East & Africa Comparative Growth Outlook |
FIGURE 15 Global CBD Market – Competitive Landscape Positioning Map, 2026 |
FIGURE 16 Global CBD Market – Estimated Revenue Share of Leading Players, 2025 (%) |
FIGURE 17 Global CBD Market – Regulatory Milestone Timeline, 2023–2030 |
FIGURE 18 Global CBD Market – Segment Growth Rate Comparison, 2026–2035

Certified Researchers

Enquiry

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Source	Hemp; Marijuana	Hemp	Marijuana
By End Use	Pharmaceuticals; Wellness & Personal Use; Food & Beverages; Pet Care; Others	Pharmaceuticals	Pet Care
By Product Form	Oils & Tinctures; Capsules & Softgels; Gummies & Confectionery; Topicals & Cosmetics; Beverages; Others	Oils & Tinctures	Gummies & Confectionery
By Distribution Channel	Hospital & Specialty Pharmacies; Retail Stores; E-commerce; Others	Retail Stores	E-commerce
By Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Source

Sub-Segment	Key Trend
Hemp	Cross-border movement under industrial commodity rules sustains volume leadership.
Marijuana	Full-spectrum preference in adult-use states drives premium pricing and faster growth.

Source choice is now a market-access decision rather than a formulation one. Producers increasingly run parallel hemp and marijuana supply chains so a single brand can serve export-eligible and domestic-premium channels without reformulating.

By End Use

Sub-Segment	Key Trend
Pharmaceuticals	Reimbursed indications and prescriber confidence anchor value leadership
Wellness & Personal Use	Sleep, stress and recovery claims dominate consumer positioning.
Food & Beverages	Fast-onset emulsions convert occasional buyers into repeat purchasers.
Pet Care	Highest growth rate of any end use, with strong repeat-purchase behaviour
Others	Research and industrial applications remain small but stable.

End-use economics are diverging sharply. Pharmaceutical and veterinary channels reward clinical investment and prescriber relationships, while consumer wellness increasingly competes on brand and format innovation rather than cannabinoid content.

By Product Form

Sub-Segment	Key Trend
Oils & Tinctures	Share erodes gradually as newer buyers reject dosing friction
Capsules & Softgels	Familiar supplement format retains older demographic loyalty.
Gummies & Confectionery	Highest new-user conversion rate across all formats
Topicals & Cosmetics	Lighter regulatory burden speeds market entry across jurisdictions.
Beverages	Nanoemulsion onset gains unlock alternative-to-alcohol positioning.
Others	Inhalables and transdermals serve niche therapeutic needs.

Format is where margin now lives. As input costs fall, brands defending price do so through delivery performance and sensory experience rather than raw cannabinoid concentration.

By Distribution Channel

Sub-Segment	Key Trend
Hospital & Specialty Pharmacies	Positioned to expand sharply if rescheduling finalises
Retail Stores	Largest share but rising private-label pressure on margin
E-commerce	Subscription models lift order values and lifetime revenue.
Others	Practitioner and wholesale routes serve professional buyers.

Channel strategy increasingly determines which brands survive consolidation. Operators with owned digital audiences sidestep advertising restrictions, while those dependent on third-party retail face both shelf-fee inflation and private-label substitution.

By Geography

Sub-Segment	Key Trend
North America	Rescheduling outcome reshapes pharmacy access and tax economics
Europe	Novel food authorisations gate ingestible category expansion
Asia-Pacific	Statutory reform in Japan and Thailand opens new demand pools.
South America	Export-grade cultivation and expanding prescription registries
Middle East & Africa	Pharmaceutical-only frameworks concentrate value in registered products.

Geographic strategy follows regulatory calendars, not consumer surveys. Firms that register dossiers ahead of statutory implementation consistently capture distribution positions that later entrants must acquire at a premium.

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”